Updates on Inhaled Insulin: Reaching for the Stars in Post-Prandial Glucose Control

Sunday, April 2, 2017
7:00 – 9:30 PM
Hyatt Regency Orlando- Regency Ballroom S 
 
This activity is supported by an educational grant from MannKind Corporation

CLICK "BEGIN" TO EVALUATE SESSIONS, CLAIM CME, AND PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, and other healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, participants will:
• Have increased knowledge regarding
– New safety and efficacy data for ultra-rapid-acting insulin
 
• Have greater competence related to
– Selection of patients who are appropriate candidates for rapid-acting insulin
– Patient education points for use of inhaled insulin therapy
– Effective use of ultra-rapid insulin therapy in clinical practice

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Diabetes and Glucose Metabolism
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 2.25 AMA PRA Category 1 Credits™
  • 2.25 CME Certificate of Participation
Course opens: 
03/30/2017
Course expires: 
04/02/2018
Rating: 
0

Program Director

Jeremy H. Pettus MD
Assistant Professor
Division of Endocrinology
University of California, San Diego
La Jolla, California
 
Faculty
Bruce W. Bode, MD
President
Atlanta Diabetes Associates
Clinical Associate Professor of Medicine,
Emory University School of Medicine
Atlanta, Georgia
 
Janet B. McGill, MD
Professor of Medicine
Division of Endocrinology, Metabolism, and Lipid Research
Washington University School of Medicine
St. Louis, Missouri
 
 

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Bruce W. Bode, MD: Consultant, AstraZeneca, GlaxoSmithKline, Insulet, Janssen, Medtronic, Novo Nordisk, Sanofi; Speaker, AstraZeneca, GlaxoSmithKline, Insulet, Janssen, Medtronic, Novo Nordisk, Sanofi; Researcher, Abbott, GlaxoSmithKline, Lilly, Mannkind, Medtronic, Novo Nordisk, Sanofi 
Janet B. McGill, MD: Advisory Group Member, Jansen Pharmaceuticals, Merck & Co.; Committee Member, Boehringer-Ingelheim; Speaker, Jansen Pharmaceuticals
Jeremy H. Pettus MD: Consultant, Novo Nordisk, Sanofi, Dexcom, Insulet, Valeritas, and mankind
 
The following SPC member who reviewed content for this activity reported relevant financial relationships:
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim

The following SPC Committee members reported financial relationships:

Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi

Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexco, Novo Nordisk, Trividia Health

Giuseppe Barbesino, MD: Spouse, employee of Genzyme

John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals

Natalie Cusano, MD: Research Support, Shire; Speaker, Shire

Joan Han, MD: Research Support, Rhythm Pharmaceutical

Alan Kelly, MD: Speaker, Eli Lilly

E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck

Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships: Connie Newman, MD, Amy Rothberg, MD

 
 

Available Credit

  • 2.25 AMA PRA Category 1 Credits™
  • 2.25 CME Certificate of Participation

Accreditation Period

Course opens: 
03/30/2017
Course expires: 
04/02/2018